Daniel Stauder
Stock Analyst at Citizens
(2.35)
# 2,512
Out of 5,179 analysts
23
Total ratings
40.91%
Success rate
3.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LMAT LeMaitre Vascular | Maintains: Market Outperform | $113 → $118 | $106.62 | +10.67% | 5 | Feb 26, 2026 | |
| ATRC AtriCure | Maintains: Market Outperform | $60 → $52 | $28.88 | +80.06% | 7 | Feb 18, 2026 | |
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $1.82 | +119.78% | 1 | Dec 16, 2025 | |
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $35.29 | +50.18% | 7 | Nov 7, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.29 | +442.64% | 1 | Mar 5, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $429.94 | +68.63% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $13.52 | - | 1 | May 7, 2024 |
LeMaitre Vascular
Feb 26, 2026
Maintains: Market Outperform
Price Target: $113 → $118
Current: $106.62
Upside: +10.67%
AtriCure
Feb 18, 2026
Maintains: Market Outperform
Price Target: $60 → $52
Current: $28.88
Upside: +80.06%
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.82
Upside: +119.78%
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $35.29
Upside: +50.18%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.29
Upside: +442.64%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $429.94
Upside: +68.63%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $13.52
Upside: -